Devyser and Sophia Genetics partner to simplify routine diagnostics using next-generation DNA sequencing

Sophia Genetics, global leader in Data-Driven Medicine, and Devyser, pioneer in diagnostic kits for complex DNA testing, announce today the signing of a new partnership to simplify the adoption of Next-Generation DNA Sequencing (NGS) for routine diagnostic laboratories. Under the terms of the agreement, Sophia Genetics’ advanced analytical platform, Sophia DDM®, will support Devyser’s NGS diagnostic kits for hereditary breast cancer (Devyser BRCA) and cystic fibrosis (Devyser CFTR).

Ulf Klangby, CEO and co-founder of Devyser, says, “We are very excited to offer NGS technology that has the capacity to revolutionize genetic testing. This solution will relieve laboratories from the burden of labor-intensive and complex workflows so that they can really focus on diagnostics. Our partnership will help continue to reduce the diagnostic turnaround time from days to hours, enabling laboratories to significantly improve their efficiency and cut costs.”

Jurgi Camblong, CEO and founder of Sophia Genetics, comments, “We are very pleased to broaden the choice of NGS kits supported by Sophia DDM®. Our fast-growing clinical genomics community will be able to leverage Devyser’s reliable and easy-to-use products to obtain clinical grade results on Sophia DDM®. This partnership continues to help laboratories unlock the power of NGS with record-low turnaround time, improving both diagnostics and treatment options for patients.”

Sophia Genetics’ and Devyser’s joint effort will immediately be launched worldwide to help routine diagnostic laboratories transition to NGS and obtain improved throughput, reduced hands-on time and trusted results. The solutions will be available through Devyser’s distribution network and to the more than 170 member hospitals of the Sophia DDM® clinical genomics community.

About Sophia Genetics

Sophia Genetics, a global leader in Data-Driven Medicine, brings together expertise in genetics, bioinformatics, machine-learning and genomic privacy. Based in Switzerland, the company is known for its high medical standards and Swiss precision when it comes to accuracy and quality management. Sophia Genetics offers bioinformatics analysis, quality assurance and secure banking of patient DNA sequence data generated by NGS to health professionals performing clinical genetic testing. Sophia Genetics does not hold personal information on patients and the patient data held is anonymised. Sophia Genetics helps clinical laboratories to reduce the cost, overcome complexity and fulfil quality constraints related to the use of NGS in the clinic. For more information, visit www.sophiagenetics.com and follow @SophiaGenetics and @JurgiCamblong.

About Devyser

Devyser is specialized in the development, manufacture and sales of diagnostic kits for complex DNA testing within oncology, reproductive health and hereditary diseases. The products are used to guide targeted cancer therapies, to enable rapid prenatal diagnostics, as well as in a wide array of genetic tests. Devyser’s product development focuses on simplifying and streamlining complex testing processes to improve throughput, reduce hands-on time and produce accurate and trusted results. Support and customer care is provided through in-house experts. Founded in 2004 and based in Stockholm, Sweden, Devyser provides genetic tests to diagnostic laboratories in over 50 countries worldwide, both through its distributor network and directly to laboratories. Find out more about Devyser at www.devyser.com and follow at: www.linkedin.com/company/devyser-ab